Neurocrine holds 2025 annual meeting; shareholders approve new equity plan and amended ESPP

NEUROCRINE BIOSCIENCES INC

Four Class II directors elected for three-year terms expiring 2028: Kyle Gano, Richard Pops, Shalini Sharp, Stephen Sherwin (each >72M votes).
Advisory say-on-pay approved: ~78M for, ~6M against, ~1.7M abstentions.
2025 Equity Incentive Plan approved: ~72.6M for, ~12.9M against.
Amended and Restated 2018 ESPP approved: ~85.4M for, ~138K against.
Ratification of Ernst & Young as independent auditor for FY2025 approved: ~85M for, ~5.2M against.

item 5.02item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.